Evaluating quality and quantity of life in breast cancer adjuvant trials

It is my view that researchers primarily interested in improving quality of life and those primarily interested in improving survival should collaborate on the next generation of two of adjuvant trials. Results of this effort should be reported at our meetings and in our journals. If the fruits of this collaboration are clinically useful, it will be self sustaining. If they are not, there will be little justification for its continuation no matter how strongly we feel about quality of life for our patients.